Total Payments
$59,773
2024 Payments
$9,390
Companies
9
Transactions
26
Medicare Patients
1,521
Medicare Billing
$134,188
Payment Breakdown by Category
Consulting$46,303 (77.5%)
Other$8,257 (13.8%)
Research$2,850 (4.8%)
Travel$1,412 (2.4%)
Food & Beverage$950.67 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $46,303 | 11 | 77.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000 | 1 | 10.0% |
| Unspecified | $2,850 | 2 | 4.8% |
| Honoraria | $2,257 | 1 | 3.8% |
| Travel and Lodging | $1,412 | 4 | 2.4% |
| Food and Beverage | $950.67 | 7 | 1.6% |
Payments by Type
General
$56,923
24 transactions
Research
$2,850
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41,403 | 7 | $0 (2024) |
| Amgen Inc. | $6,000 | 1 | $0 (2023) |
| Celgene Corporation | $4,315 | 3 | $0 (2018) |
| PFIZER INC. | $3,574 | 7 | $0 (2022) |
| Horizon Therapeutics plc | $2,257 | 1 | $0 (2022) |
| PRINCIPIA BIOPHARMA INC. | $1,350 | 1 | $0 (2021) |
| EMD Serono, Inc. | $700.00 | 2 | $0 (2022) |
| GlaxoSmithKline, LLC. | $92.23 | 1 | $0 (2019) |
| ABBVIE INC. | $82.36 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,390 | 4 | E.R. Squibb & Sons, L.L.C. ($9,308) |
| 2023 | $16,220 | 2 | E.R. Squibb & Sons, L.L.C. ($10,220) |
| 2022 | $17,562 | 5 | E.R. Squibb & Sons, L.L.C. ($13,505) |
| 2021 | $8,320 | 4 | E.R. Squibb & Sons, L.L.C. ($6,570) |
| 2020 | $1,800 | 1 | E.R. Squibb & Sons, L.L.C. ($1,800) |
| 2019 | $243.82 | 2 | PFIZER INC. ($151.59) |
| 2018 | $6,237 | 8 | Celgene Corporation ($4,315) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $34.05 | General |
| Category: IMMUNOLOGY | ||||||
| 09/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $33.44 | General |
| Category: IMMUNOLOGY | ||||||
| 03/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $9,307.50 | General |
| 06/21/2023 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Inflammation | ||||||
| 06/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $10,220.00 | General |
| 12/30/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $8,577.50 | General |
| 09/15/2022 | PFIZER INC. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | ||||||
| 07/26/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,927.50 | General |
| 01/25/2022 | Horizon Therapeutics plc | — | Honoraria | Cash or cash equivalent | $2,257.16 | General |
| 01/12/2022 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 12/28/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,190.00 | General |
| 09/29/2021 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,380.00 | General |
| 09/01/2021 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 04/07/2021 | PRINCIPIA BIOPHARMA INC. | — | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia | ||||||
| 11/12/2020 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 04/07/2019 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $92.23 | General |
| Category: IMMUNOLOGY | ||||||
| 03/05/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $151.59 | General |
| 07/26/2018 | Celgene Corporation | Otezla (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Dermatology | ||||||
| 05/19/2018 | Celgene Corporation | Otezla (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Dermatology | ||||||
| 05/19/2018 | Celgene Corporation | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $114.53 | General |
| Category: Dermatology | ||||||
| 05/10/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $86.62 | General |
| 02/24/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $641.84 | General |
| 02/24/2018 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $509.96 | General |
| 02/24/2018 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $389.76 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF PF06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | PFIZER INC. | $1,500 | 1 |
| An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia | PRINCIPIA BIOPHARMA INC. | $1,350 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 424 | 833 | $187,183 | $40,462 |
| 2022 | 9 | 371 | 710 | $147,761 | $33,311 |
| 2021 | 9 | 402 | 787 | $170,866 | $38,387 |
| 2020 | 9 | 324 | 564 | $113,708 | $22,027 |
Total Patients
1,521
Total Services
2,894
Medicare Billing
$134,188
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 96 | 133 | $45,752 | $11,870 | 25.9% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 18 | 92 | $34,776 | $8,760 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 69 | $16,008 | $4,490 | 28.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 36 | 43 | $16,641 | $2,890 | 17.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 61 | 79 | $21,093 | $2,773 | 13.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $10,660 | $2,418 | 22.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 18 | 24 | $8,736 | $1,830 | 21.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 56 | 309 | $13,596 | $1,461 | 10.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $6,593 | $1,446 | 21.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 13 | 13 | $6,318 | $1,317 | 20.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 13 | 18 | $3,762 | $687.99 | 18.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 14 | $3,248 | $518.80 | 16.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 151 | $51,944 | $14,541 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $13,325 | $2,988 | 22.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 61 | 73 | $19,491 | $2,919 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 50 | $11,600 | $2,914 | 25.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 26 | 29 | $10,556 | $2,503 | 23.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 27 | 33 | $12,771 | $2,442 | 19.1% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 12 | 16 | $4,992 | $1,555 | 31.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 52 | 295 | $12,980 | $1,507 | 11.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 16 | $5,504 | $1,019 | 18.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 11 | 22 | $4,598 | $923.93 | 20.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 108 | 171 | $58,824 | $16,061 | 27.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 30 | $13,920 | $3,575 | 25.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 53 | $12,296 | $3,193 | 26.0% |
About Dr. Benjamin Chong, M.D
Dr. Benjamin Chong, M.D is a Dermatology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1679782163.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Chong, M.D has received a total of $59,773 in payments from pharmaceutical and medical device companies, with $9,390 received in 2024. These payments were reported across 26 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($46,303).
As a Medicare-enrolled provider, Chong has provided services to 1,521 Medicare beneficiaries, totaling 2,894 services with total Medicare billing of $134,188. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Dallas, TX
- Active Since 05/21/2007
- Last Updated 05/04/2015
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1679782163
Products in Payments
- Otezla (Drug) $10,315
- BENLYSTA (Biological) $92.23
- SKYRIZI (Biological) $82.36
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Dallas
Dr. Jennifer Cather, M.d, M.D
Dermatology — Payments: $1.8M
Dermatology $1.8M
Dr. Joseph Merola, M.d., M.m.sc, M.D., M.M.SC
Dermatology — Payments: $1.7M
Dermatology $1.7M
Dr. Martin Menter, Md, MD
Dermatology — Payments: $1.1M
Dermatology $1.1M
Dr. So Yeon Paek, M.d, M.D
Dermatology — Payments: $637,453
Dermatology $637,453
Dr. William Abramovits, M.d, M.D
Dermatology — Payments: $634,225
Dermatology $634,225
Dr. Ross Radusky, M.d, M.D
Dermatology — Payments: $598,043
Dermatology $598,043